联合剂吸入对慢性阻塞性肺疾病病人生活质量的影响  

Study on the effect of joint inhalation of glucocorticoid and long actingβ_2 receptor antagonist on pulmanary function in patients with COPD

作　　者：尹建云[1] 王丹琪[1] 王继红[1] 

机构地区：[1]北京积水潭医院内科门诊,北京100035

出　　处：《护理管理杂志》2007年第8期39-40,共2页Journal of Nursing Administration

摘　　要：目的对慢性阻塞性肺疾病缓解期病人应用吸入型糖皮质激素及吸人型长效β_2受体激动剂联合冶疗,评价其对慢性阻塞性肺疾病缓解期病人生活质量及肺功能的影响。方法将60例慢性阻塞性肺疾病缓解期病人随机分为实验组和对照组,实验组联合吸入糖皮质激素及长效β_2受体激动剂,对照组吸入短效β_2受体激动剂及口服支气管扩张剂,在治疗前及治疗1年后分别测定两组病人的肺功能及6min步行试验。结果实验组治疗1年后肺功能FEV_1、FEV_1占预计值百分比较治疗前有明显改善(P<0.01),而对照组无明显改善(P>0.05);治疗后6 min行走距离差值,实验组与对照组比较有明显提高(P<0 05);治疗1年后,两组在步行后呼吸困难及疲劳评分比较差异具有统计学意义(P<0.01),实验组明显优于对照组。Objective To evaluate the effect of joint inhalation of glucocorticoid and long actingβ2 receptor antagonist on the pulmonary function in patients with chronic obstructive pulmonary disease （ COPD）. Methods Sixty patients with COPD were randomly assigned into two groups. The patients in experimental group inhaled glucocorticoid and long acting β2 receptor antagonist,while the patients in control group inhaled short acting β2 receptor antagonist and took bronchodilator orally. Then,patients＇ pulmonary function and six - minute walking test were assessed before and one year after the treatment. Results The pulmonary function index of FEVt showed significant improvement after the treatment in experimental group （P 〈 0.01 ） ,while there was no significant improvement in control group （P 〉 0.05 ）. There was also significant difference in the results of six - minute walking test between the two groups （P 〈 0.05）. Conclusion Joint inhalation of glucocorticoid and long acting β2 receptor antagonist can improve the pulmonary function and quality of life in patients with COPD.

关 键 词：慢性阻塞性肺疾病 肺功能 吸入剂 6 min行走试验 生活质量 

分 类 号：R473.5[医药卫生—护理学]